M itochondria play a critical role in energy homeostasis as the primary site of adenosine triphosphate production. Energy regulation is also dependent on proteins translated from genes encoded in mitochondrial DNA (mtDNA), a 16.7-kb circular DNA molecule. Mitochondrial dysfunction, a hallmark of the aging process, disrupts energy homeostasis and is believed to be a core component of several chronic conditions including cardiovascular disease (CVD). 1 Mitochondrial dysfunction may also play a critical role in the initiation and progression of atherosclerosis, the primary pathological lesion underlying CVD. Evidence for this hypothesis is derived from both model organisms and human studies. First, in ApoE knockout mouse models of hyperlipidemia, mtDNA damage occurs prior to plaque formation, and there is significant correlation between mtDNA damage and extent of atherosclerosis in ApoE and human aorta specimens. 2 Second, a study using polG knockout mice (which results in elevated rates of mtDNA mutations) and bone marrow transplants into ApoE knockout mice demonstrated that circulating cells increased the necrotic core and decreased the fibrous cap, which are key features of plaque instability. 3 Finally, in humans, white blood cell (WBC) mtDNA damage has been associated with highrisk atherosclerotic plaques. 3 Mitochondrial DNA copy number (mtDNA-CN), while not a direct measure of mtDNA damage, is associated with mitochondrial enzyme activity and adenosine triphosphate production 4 and can therefore serve as a biomarker of mitochondrial function. Mitochondrial DNA-CN, a measure of mtDNA levels per cell, is quantified using a low-cost scalable assay that allows for rapid determination of mitochondrial function in a large number of samples. Mitochondrial DNA-CN declines with age 5 and is associated with all-cause mortality 6 and chronic kidney disease 7 in longitudinal studies. A 2017 small case-control study 8 has also
shown an association between peripheral blood mtDNA-CN and severity of coronary heart disease. 8 We measured mtDNA-CN in DNA derived from blood samples in 21 870 individuals from 3 prospective cohort studies, the Atherosclerosis Risk in Communities (ARIC) study, the Cardiovascular Health Study (CHS), and the Multiethnic Study of Atherosclerosis (MESA), to evaluate the association of mtDNA-CN with prevalent and incident CVD events and the potential utility of mtDNA as a novel clinical biomarker of CVD risk.
Methods

Study Populations
The ARIC study recruited 15 792 individuals aged 45 to 65 years between 1987 and 1989 from 4 US communities. 9 Twentyseven percent of ARIC participants were African American. Our analysis was restricted to 11 455 unrelated participants who met quality control metrics implemented for genotyping arrays (used to generate the mtDNA-CN metric). 10 We further excluded 302 individuals missing CVD risk factor or status information. The final sample size was 11 153 individuals. The CHS study recruited 5201 individuals older than 65 years between 1989 and 1990 from 4 US communities. 11 In 1992 to 1993, CHS further recruited 687 African American participants to increase minority enrollment. Our analysis was restricted to 4892 individuals with nonmissing mtDNA-CN measurements. We further excluded 62 individuals missing CVD risk factor or status information. The final sample size was 4830 individuals. The MESA study recruited 6814 individuals aged 45 to 85 years free of prevalent CVD between 2000 and 2001 from 6 US communities. 12 The study included white individuals (38%), African American individuals (28%), Chinese American individuals (12%), and Hispanic individuals (22%). The present analysis was restricted to 6179 individuals with nonmissing mtDNA-CN measurements. We further excluded 263 individuals whose DNA was from the MESA family study because this DNA was derived from transformed cell lines. We further excluded 5 participants from racial/ethnic groups at centers in which there were fewer than 5 participants from the same racial/ethnic group as well as 24 individuals missing CVD risk factor or status information. The final sample size was 5887 individuals. All centers obtained approval from their respective institutional review boards, and all participants provided written informed consent. This analysis was conducted with anonymized data and acknowledged as not human participants research by the Johns Hopkins Medicine institutional review board.
Measurement of mtDNA-CN
DNA for mtDNA-CN analysis was collected at different visits in each study. For this analysis, the visit of DNA collection was considered the baseline visit (eMethods in the Supplement). In ARIC, DNA was extracted using the Gentra Puregene Blood Kit (Qiagen) from buffy coat of whole blood collected in visits 1 (1987-1989) , 2 (1990-1992) , 3 (1993-1995) , and 4 (1996-1998) in 4.2%, 79.6%, 15.6%, and 0.6% of participants, respectively. In CHS, DNA was extracted by salt precipitation following proteinase K digestion of buffy coat from whole blood collected at visit 1. In MESA, DNA was isolated from peripheral leukocytes from blood collected at visit 1 using the Gentra Puregene Blood Kit.
The methods for measuring mtDNA-CN have been previously described. 7 Briefly, in ARIC and MESA, mtDNA-CN was calculated from probe intensities of mitochondrial singlenucleotide polymorphisms on the Affymetrix Genome-Wide Human SNP Array 6.0 7 (Genvisis), and batch effects, DNA quality, and starting DNA quantity were corrected using probe intensities from nuclear single-nucleotide polymorphisms (eMethods in the Supplement). In CHS, mtDNA-CN was measured using multiplexed TaqMan-based quantitative polymerase chain reaction as previously described, 6 and batch effects were corrected using a linear mixed model (eMethods in the Supplement). Standardized residuals after adjusting for known influences on mtDNA-CN (age, sex, collection site, and race/ethnicity) were used as the mtDNA-CN metric for all analyses (ie, with a mean of 0 and SD of 1).
Cardiovascular Disease Risk Factors
Traditional CVD risk factors were measured across all 3 cohorts at each clinic visit. Race/ethnicity and smoking status were assessed by self-report. Details for measurements of total cholesterol, high-density lipoprotein cholesterol, blood pressure, and medication use for the 3 cohorts have been previously described. consisted of expert committee review of hospital records, telephone interviews, and death certificates. Prevalent coronary heart disease (CHD) was defined as self-or physicianreported history of myocardial infarction (MI) or cardiac procedures (coronary artery bypass grafting or coronary artery angioplasty) at baseline. In addition, adjudicated events between visit 1 and the baseline visit for this study were considered prevalent events. Prevalent stroke was defined as self-or physician-reported stroke at baseline. Incident CHD was defined as the first incident MI or death owing to CHD. Incident stroke was defined as the first nonfatal stroke or death owing to stroke. Incident CVD included both incident CHD and stroke. Analyses for incident events were performed across all 3 studies after excluding participants with prevalent CVD at baseline in ARIC and CHS.
Statistical Analyses
For the primary analysis, we used mtDNA-CN as a continuous variable and evaluated the change in risk of study outcomes associated with a 1-SD decrease in mtDNA-CN. As secondary analysis, we categorized mtDNA-CN in quintiles based on the distribution within each cohort and compared the risk of study outcomes in quintiles 1 through 4 with quintile 5. We used logistic regression to model odds ratios (ORs) and 95% CIs for the association of mtDNA-CN with prevalent outcomes. For incident outcomes (adjudicated as described in the previous section), followup time was defined from baseline (DNA collection) through the development of a study end point, death, or loss to/end of followup (through 2011 in ARIC, 2014 in CHS, and 2012 in MESA). We used Cox proportional hazards regression to estimate the hazard ratios (HRs) and 95% CIs for the association between mtDNA and incident outcomes. For incident outcomes, we also calculated marginally adjusted incidence rates and adjusted incidence rate ratios using Poisson regression.
The model adjustments for both prevalent and incident disease included adding the following covariates: age, sex, collection center, and race/ethnicity in the base model (model 1) and additionally, total cholesterol, high-density lipoprotein cholesterol, systolic blood pressure, hypertension medication use, current smoking, and diabetes in the full model (model 2). Cox models were fit separately for each cohort and combined across cohorts using fixed-effects meta-analysis ("meta.summaries" function from the "rmeta" R package 18 ). Forest plots were generated using the "forestplot" R package (R Programming). 19 We conducted additional analyses to evaluate whether mtDNA-CN may improve discrimination and reclassification of study participants when added to the PCE (eMethods in the Supplement). Briefly, we compared the discrimination ability of the calculated 10-year risk score vs the combination of the 10-year risk score and mtDNA-CN using Harrell C statistics. We also examined whether adding mtDNA-CN could improve the net reclassification index (NRI) and/or integrated discrimination improvement for statin therapy 20 based on the 2013 ACC/ AHA recommendations for starting statin therapy, excluding individuals whose risk score would not affect therapy decisions based on the 2013 ACC/AHA guidelines (ie, prevalent CVD, older than 75 years, prevalent diabetes, high-density lipoprotein cholesterol levels <70 mg/dL, or low-density lipoprotein cholesterol levels ≥190 mg/dL [to convert to millimoles per liter, multiply by 0.0259]). The NRI reflects the net increment in prediction accuracy (defined as the proportion of patients classified to a correct category) comparing models with and without mtDNA-CN, while the integrated discrimination improvement reflects the change in calculated risk for each individual comparing models with and without mtDNA-CN. We also performed prespecified subgroup analyses by race/ ethnicity, sex, and age and tested for potential interactions by adding an interaction term to the regression model. Finally, because mtDNA-CN from peripheral blood is associated with WBC count, we further adjusted the model by including logtransformed WBC count as a covariate among 8726 participants in ARIC in whom WBC measurements were available. All statistical analyses were performed using R, version 3.2.2 (R Programming). A 2-sided P value of less than .05 was considered significant.
Results
The study included 11 153 participants from ARIC, 4830 participants from CHS, and 5887 participants from MESA (total sample size, 21 870). The mean age of study participants was 62.4 years (ARIC, 57.9 years; MESA, 62.4 years; and CHS, 72.5 years), and 54.7% of participants were women (n = 11 967) (eTable 1 in the Supplement). Comparing age-and sex-adjusted quintiles of mtDNA-CN, individuals in the highest quintile of mtDNA had significantly more favorable CVD risk factor profiles, with the exception of total cholesterol levels (while not significant, higher total cholesterol levels were observed in quintile 5).
Prevalent Disease
One thousand seven hundred seven participants had prevalent CVD at baseline (1003 in ARIC and 704 in CHS; MESA recruitment excluded prevalent CVD). The meta-analysis ORs for prevalent CHD, stroke, and CVD associated with a 1-SD decrease in mtDNA-CN were 1.26 (95% CI, 1.20-1.33), 1.25 (95% CI, 1.14-1.36), and 1.27 (95% CI, 1.21-1.34), respectively, after adjusting for age, sex, race/ethnicity, and collection center (eFigure 1 in the Supplement and Table 1 , model 1). Incorporating additional traditional CVD risk factors resulted in modest attenuation of the ORs (Table 1 , model 2). The associations were consistent in the 4-study race/ ethnicity and sex groups evaluated except in African American participants in CHS, although the sample size in this group was small (n = 753; 112 CVD events) (eFigures 2 and 3 in the Supplement).
Incident Disease
Participants free of CVD at baseline (n = 20 163) were followed up for a mean of 13.5 years, with 3665 incident CVD events (2460 incident CHD episodes and 1584 incident strokes). The pooled HRs for incident CHD, stroke, and CVD associated with a 1-SD decrease in mtDNA-CN were 1.29 (95% CI, 1.24-1.33), 1.11 (95% CI, 1.06-1.16), and 1.23 (95% CI, 1.19-1.26), respectively, after adjusting for age, sex, race/ethnicity, and study center (Figure) . A modest attenuation of the HR was observed on the inclusion of traditional CVD risk factors ( Table 2 , model 2). The associations were consistent across study race/ ethnicity and sex groups, although stronger associations were observed in ARIC compared with CHS (eFigures 4 and 5 and eTable 2 in the Supplement).
Given that mtDNA-CN is influenced by WBC count, 7 we tested whether inclusion of log-transformed WBC as an additional covariate to model 1 attenuated the association with incident CVD in ARIC participants who had both mtDNA-CN and WBC count measured (8726, with 794 incident CVD events), with similar HRs observed (model 1, HR, 1.40; 95% CI, 1.34-1.46; model 1 + log(WBC), HR, 1.36; 95% CI, 1.30-1.43). Age Interaction of Association of mtDNA-CN on CVD
In our analysis, the effect of mtDNA-CN on incident CVD was significantly larger in ARIC compared with CHS (Table 2) , despite observing moderately larger effect sizes for prevalent CVD in CHS (Table 1) . A major difference in these cohorts is the age distribution; on average, ARIC participants were 14.6 years younger (mean for ARIC, 57.9 years; range, 44.9-74.1 years vs mean CHS, 72.5 years; range, 65.0-100.0 years). The MESA cohort (mean, 62.4 years; range, 44-84 years) included participants that spanned the age distribution of both cohorts. Stratifying MESA to those younger than 65 years and 65 years or older, there was a consistent trend of mtDNA-CN having a stronger association for all 3 incident outcomes in younger vs older MESA participants (eTable 3 in the Supplement, Figure) . While a formal test for interaction between mtDNA-CN and age was not significant in any individual study, the interaction term was highly significant in the combined analysis (OR, 1.0106; 95% CI, 1.0072-1.0140; P < .001), and significant even when excluding the oldest cohort, CHS (OR, 1.0061; 95% CI, 1.0008-1.0115; P = .03).
Mitochondrial DNA-CN and Risk Discrimination and Reclassification
Adding mtDNA-CN to the ACC/AHA 2013 PCE risk equation improved discrimination for CVD events in the pooled ARIC, CHS, and MESA cohorts (ΔC statistic, 0.7%; 95% CI, 0.4 to 1.0), although this was largely driven by the improvement for CHD risk (ΔC statistic, 1.2%; 95% CI, 0.8 to 1.6) because no improvement was seen for estimating stroke risk (ΔC statistic, −0.2%; 95% CI, −0.5 to 0.2) ( Table 3 and eTable 4 in the Supplement).
We also assessed the ability of mtDNA-CN to improve risk reclassification in the 14 084 individuals who met the ACC/ AHA risk evaluation criteria for primary prevention (age 40 to 75 years, free of type 2 diabetes, no CVD history, and highdensity lipoprotein cholesterol levels ≥70 mg/dL and lowdensity lipoprotein cholesterol levels <190 mg/dL). Adding mtDNA-CN to the PCE improved risk reclassification for CVD events, measured by continuous NRI (0.194; 95% CI, 0.130-0.258; P < .001) and by integrated discrimination improvement (0.009; 95% CI, 0.005-0.012; P < .001) ( Table 4) . Looking at the overall categorical NRI with cutoffs at 5% and 7.5%, we also observed a significant improvement for CVD risk reclassification (overall NRI, 0.032; 95% CI, 0.015-0.049; P < .001) (Table 4) , although this is largely driven by CHD (eTable 5 in the Supplement). Overall, a net of 15 individuals with events were appropriately upclassified, and 221 individuals without events were appropriately downclassified. Using a hard cutoff of 7.5% 10-year ASCVD risk for initiating statin therapy, a net of 6 additional individuals would appropriately be statin eligible, and 139 would be appropriately not recommended to initiate statin therapy. However, using the PCE for this analysis could be biased by poor calibration. Indeed, the observed risk in those estimated to have 5% to 7.5% risk was 5.0%, suggesting that the PCE overestimated risk in our sample. In recalibrated models, the observed risk in the 5% to 7.5% risk category was 5.6%. Comparing the recalibrated model with and without mtDNA-CN, we still observed significant improvement for both overall categorical and continuous NRI as well as integrated discrimination improvement (Table 4) .
Discussion
We explored the role of mtDNA-CN in cardiovascular disease in 21 870 participants from the ARIC, CHS, and MESA studies, including self-identified white, black, Hispanic, and Chinese individuals. Mitochondrial DNA-CN was inversely associated with both prevalent and incident CVD events, and it also demonstrated potential as a clinically useful predictor of CVD by improving risk prediction and reclassification for primary hard ASCVD prevention compared with the 2013 ACC/AHA PCE risk prediction. While an association between prevalent CHD and mtDNA-CN has been reported in a small case-control study, 21 to our knowledge, this is the first time that mtDNA-CN has been shown to be associated with incident CVD. In our analyses, the association of mtDNA-CN with incident CHD was stronger than with incident stroke. While CHD and stroke have overlapping risk factors, the risk factors play different roles in precipitating these outcomes. 22 Indeed, while most CHD occurs in the setting of coronary atherosclerosis, the etiology of stroke is more diverse, including a confluence of atherosclerosis, cardiac embolism, and small vessel disease. Thus, one possible explanation for the stronger association with CHD is that mtDNA-CN is associated with the atherosclerotic processes that precipitate CHD, although additional work is required to validate this hypothesis. We also observed significantly larger effect estimates of mtDNA-CN on CVD risk in younger individuals. One concern was that this result was driven by the different methods used to measure mtDNA-CN across the cohorts (which have different recruitment age ranges). We have some evidence suggesting that genotyping array-based methods to measure mtDNA-CN (ARIC and MESA) are more biologically relevant than quantitative polymerase chain reaction (CHS) (eTable 6 in the Supplement). However, the observation that the association with prevalent CVD was actually stronger in the oldest cohort (CHS) suggests that excluding prevalent disease may induce selection (survivor) bias by excluding from the longitudinal analyses individuals at highest risk for CVD owing to reduced mtDNA-CN by virtue of having prevalent disease. Indeed, this age-related attenuation of CVD risk factors has been observed for other risk factors. [23] [24] [25] [26] While this study was not designed to address the mechanism by which levels of mtDNA could affect CVD risk, our results are in line with evidence supporting a role of mitochondria in cardiovascular disease. A key question remains as to whether mtDNA-CN has a causal effect, which would suggest new avenues for preventive intervention, or is a biomarker for another CVD risk factor. However, given that a significant association is observed after the inclusion of traditional CVD risk factors, such as sex, blood lipids, blood pressure, smoking status, and hypertension medication use, as covariates, our data support a role for mtDNA-CN as an independent risk factor associated with CVD events.
Strengths and Limitations
This study has several strengths and limitations. We used a large sample size combining 3 well-characterized prospective studies with long-term follow-up to assess the role of mtDNA-CN in CVD. However, the attenuation of the association with advancing age, the potential contribution of mtDNA-CN assessment method to the heterogeneity of the results, and the relatively small number of observed stroke events require additional replication of our findings in cohorts with sufficient sample size before mtDNA-CN can be formally incorporated to standard risk prediction scores. In addition, we only had a measurement of mtDNA-CN at a single point. This measurement is subject to analytical random error and to individual variability over time, and both types of errors may have contributed to underestimating the association between mtDNA-CN and CVD outcomes.
Conclusions
Mitochondrial DNA copy number was inversely associated with incident and prevalent CVD outcomes in 21 870 participants from 3 well-characterized cohorts. In addition, mtDNA-CN was significantly associated with improved risk discrimination and reclassification for primary prevention of hard ASCVD. Role of the Funder/Sponsor: The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
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Methods
Measurement of mtDNA-CN
In ARIC, DNA was extracted using the Gentra Puregene Blood Kit (Qiagen) from the buffy coat of whole blood collected in visits 1 (1987-1989) , 2 (1990-1992) , 3 (1993-1995) , and 4 (1996-1998) in 4.2, 79.6, 15.6 and 0.6% of participants, respectively. In CHS, DNA was extracted by salt precipitation following proteinase K digestion of the buffy coat from whole blood collected at visit 1. In MESA, DNA was isolated from peripheral leukocytes from blood collected at visit 1using the Gentra Puregene Blood Kit.
In ARIC and MESA, mtDNA-CN was calculated from probe intensities of mitochondrial single nucleotide polymorphisms (SNPs) on the Affymetrix Genome-Wide Human SNP Array 6.0 1 using the used in ARIC, as genotyping plates were confounded by CVD status. In ARIC, the raw measure of mtDNA-CN was first stratified by race, and then, using a linear regression, mtDNA-CN was adjusted for the effects of age, sex, collection center, and SVs. In MESA, the raw measure of mtDNA-CN was adjusted for the effects of age, sex, collection center, race and PCs and then a rank-based inverse normal transformation was performed to reduce the impact of outliers. The standardized residuals from these models were used as the mtDNA-CN metric for all analyses (i.e. with a mean of 0 and standard deviation of 1).
Two criteria come into play when deciding on how many PCs to include to correct for confounding variables. The first is what order to add PCs, and the second is how many to include.
Traditionally, one would include PCs in their natural order (i.e. PC1, then PC2, etc…), since the order is dictated by the maximum variance explained. However, for our study, PCs are generated on nuclear SNP probe intensity, but in fact, we are interested in explaining the variance in mtDNA-CN. Thus, we took two approaches with respect to the order in which PCs are added. First, PCs were either taken in their natural order or alternatively, taken from an initial pool of PCs (5% of total sample size) using a stepwise forward regression to select PCs that explain the maximal variance of the raw estimates of mtDNA-CN ("rank order"). With regards to the number of PCs to add, we either used a fixed number (the top 15 PCs) or PCs were added in rank order until they no longer significantly improved the model (P > 0.05 after Bonferroni correction for the number of PCs tested; 152 PCs and 95 PCs for ARIC and MESA, respectively). Note that the "rank order" does not apply to SVs, as SVs are not necessarily orthogonal, and the number of SVs is pre-specified for analysis, with all SVs generated included in the model. Thus, we used the number of PCs derived from the forward regression to determine the number of SVs to include. We tested the performance of these 2 approaches in ARIC (SV15 and SV152) and 4 approaches in MESA (PC15 natural, PC15 rank, PC95 natural, PC95 rank) utilizing several criteria: 1) known associations with sex and age; 2) correlation with alternative mtDNA-CN estimates (wholegenome sequence on 400 individuals in ARIC, qPCR for ~5,400 individuals in MESA); 3) the observed association between mtDNA-CN and white blood cell count (WBC). Due to the correlation between mtDNA-CN and WBC, we hypothesized that SNPs associated with WBC count should also be associated with mtDNA-CN (uncorrected for WBC), thus providing us an independent method to evaluate our different estimates of mtDNA-CN. We specifically focused on two extremely strong signals in African Americans (rs2814778 and rs12149261) 3 , for which we are adequately powered in our sample sizes. In ARIC, SV15 showed stronger associations across all our metrics. In MESA, the results
were not as clear, with PC95 natural showing the best overall performance.
In CHS, mtDNA-CN was measured using multiplexed Taqman-based qPCR as previously described 4 . To correct for batch effects and known influences on mtDNA-CN, the raw measure of mtDNA-CN was first stratified by race, then we used a linear mixed model to adjust the raw mtDNA-CN measurement for age, sex, and collection site (fixed effects) and qPCR plate (random effect).
Standardized residuals from this model were used as the mtDNA-CN metric for all analyses (i.e. with a mean of 0 and standard deviation of 1).
Statistical Analyses
To examine whether mtDNA-CN may improve risk prediction beyond PCE, we compared the discrimination ability of the calculated 10-year risk score vs. the combination of the 10-year risk score and mtDNA-CN using Harrell's C statistics. P-value for the difference in C-statistics was obtained by bootstrapping, using 100 bootstraps (function 'censboot' in the R package 'boot') 5 . For risk prediction models, we pooled participants from ARIC, CHS, and MESA and derived pooled coefficients for mtDNA-CN after multivariable adjustments 5 . This analysis was restricted to individuals with the same criteria as described in the 2013 ACC/AHA Guideline 6 (ages 40-79 years and no prevalent CVD, atrial fibrillation, or heart failure), with follow-up time censored at 12 years. We included identical variables in the model as used in the PCE, with mtDNA-CN being the only addition. As was done for the PCE, coefficients for mtDNA-CN were estimated separately in whites and blacks, stratified by sex. For generating 10-year hard ASCD risk scores incorporating mtDNA-CN, we updated the PCE model by adding the difference between the mean linear predictor calculated in our dataset with and without mtDNA-CN.
We also examined whether adding mtDNA-CN could improve the net reclassification index (NRI) and/or integrated discrimination improvement (IDI) for statin therapy 7 , based on the 2013 ACC/AHA recommendations for starting statin therapy, excluding individuals whose risk score would not impact therapy decisions based on the 2013 ACC/AHA guidelines (i.e., prevalent CVD, age >75 years, prevalent diabetes, LDL≥190, or LDL<70). Given that NRI can be biased by poorly calibrated estimates, we generated recalibrated 10-year hard ASCVD risk scores in the pooled ARIC, CHS, and MESA cohorts, excluding individuals whose risk score would not impact the choice to initiate statin therapy. Consistent with the approach used to generate the PCE, we stratified on race and sex, and included the same variables as used to generate the PCE, including all interaction terms, with the only changes being the removal of diabetes (since this is an exclusion criteria in our analysis) and the addition of hypertension medication status. We also included a term for race in the "whites" analysis, as
Hispanics and Chinese were included in this group (per the 2013 ACC/AHA guideline recommendation to use the PCE generated in Whites for Hispanics and Asian populations). 
